加载中
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
常规交易时段
US$1.065
−US$0.085 · -7.39%
盘中时间采用ET。市场数据可能有所延迟。
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
日内区间
当前US$1.065
52周区间
当前US$1.065
盘中时间采用ET。市场数据可能有所延迟。
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
日内区间
当前US$1.065
52周区间
当前US$1.065
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 2521.56万 USD | 1999.54万 USD | 3879.06万 USD | 1651.55万 USD | 847.9万 USD |
| 销售、一般及管理费用 | 447.97万 USD | 669.95万 USD | 624.44万 USD | 899.57万 USD | 605.82万 USD |
| 营业费用 | 2969.53万 USD | 2669.49万 USD | 4503.5万 USD | 2551.13万 USD | 1453.72万 USD |
| 利息收入 | 69.91万 USD | 33.18万 USD | 66.79万 USD | 18.27万 USD | 1.33万 USD |
| 利息支出 | — | 185.32万 USD | — | — | — |
| 营业利润 | −2969.53万 USD | −2669.49万 USD | −4503.5万 USD | −2551.13万 USD | −1453.72万 USD |
| 净利润 | −2885.42万 USD | −2459.04万 USD | −5620.4万 USD | −2532.86万 USD | −1448.71万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$25.67
上涨空间 2310.33%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI209.79万0.00%2.3万亿 USD0.03%US$381-0.15%
Vanguard Extended Market ETFVXF58.65万0.00%954亿 USD0.05%US$232.12-0.60%
iShares Micro-Cap ETFIWC11.26万0.01%13.17亿 USD0.60%US$180.11-0.86%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM4万0.03%1.16亿 USD0.73%US$15.71-0.87%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
